Advertisement

Neuromuscular Diseases

  • Maisha T. RobinsonEmail author
  • Danny Estupinan
Chapter

Abstract

Neuromuscular diseases are a group of disorders affecting either central motor neurons, the neuronal pathways, the muscles themselves or a combination of those. These diseases are marked by progressive disability due to muscle weakness. Motor neuron disease, particularly amyotrophic lateral sclerosis (ALS), is a progressive and incurable neurologic condition. The treatment is primarily palliative in nature with a focus on maintaining communication and optimizing function. Given the high symptom burden associated with the disease, pharmacologic and nonpharmacologic management is provided to improve overall quality of life. As the disease progresses, functional decline is anticipated and cognitive dysfunction may also occur. Therefore, establishing goals of care early in the disease process is critical to ensure that the goals are aligned with the available treatment options. Challenging discussions regarding end-of-life care and advance care planning are recommended throughout the course of disease and certain triggers may prompt these conversations at specific time points. At the end of life, some patients may decide to transition to comfort care through hospice services, which offer support to the patient and the caregiver. The provision of palliative care for motor neuron disease requires a clinician to understand the disease trajectory, anticipate symptoms, ease suffering, and clarify the patient’s goals. More research is necessary to determine the optimal platform for the delivery of palliative care in this patient population.

Keywords

Neuromuscular Motor neuron disease Amyotrophic Lateral Sclerosis (ALS) Palliative care Symptom management Goals of care 

References

  1. 1.
    Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneapolis, Minn). 2014;20(5 Peripheral Nervous System Disorders):1185–207.Google Scholar
  2. 2.
    Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology. 2002;59(3):428–31.PubMedGoogle Scholar
  3. 3.
    Blackhall LJ. Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead. Muscle Nerve. 2012;45(3):311–8.Google Scholar
  4. 4.
    Rechtman L, Jordan H, Wagner L, Horton DK, Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Degeneration. 2015;16(1–2):65–71.Google Scholar
  5. 5.
    Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord : Off Publ World Fed Neurol, Res Group Mot Neuron Dis. 2000;1(5):293–9.Google Scholar
  6. 6.
    Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9:483–9.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Woolley SC, Strong MJ. Frontotemporal dysfunction and dementia in amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):787–805.PubMedGoogle Scholar
  8. 8.
    Rooney J, Byrne S, Heverin M, et al. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995–2010. PLoS One. 2013;8(9):e74733.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25(5):709–14.PubMedGoogle Scholar
  10. 10.
    Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler : Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2009;10(5–6):310–23.Google Scholar
  11. 11.
    Moura MC, Novaes MR, Eduardo EJ, Zago YS, Freitas Rdel N, Casulari LA. Prognostic factors in amyotrophic lateral sclerosis: a population-based study. PLoS One. 2015;10(10):e0141500.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Cedarbaum JM, Stambler N. Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials. J Neurol Sci. 1997;152(Suppl 1):S1–9.PubMedGoogle Scholar
  13. 13.
    Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1–2):13–21.PubMedGoogle Scholar
  14. 14.
    Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler : Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2010;11(1–2):178–80.Google Scholar
  15. 15.
    Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.Google Scholar
  16. 16.
    Miller RG, Brooks BR, Swain-Eng RJ, et al. Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013;81(24):2136–40.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother. 2017;18(7):735–8.PubMedGoogle Scholar
  18. 18.
    Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. Writing Group; Edaravone (MCI-186) ALS 19 Study Group 2017;16(7):505–12.Google Scholar
  19. 19.
    Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012;46(1):1–12.PubMedGoogle Scholar
  20. 20.
    Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62(3):743–66.Google Scholar
  21. 21.
    D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord : NMD. 1994;4(5–6):497–502.PubMedGoogle Scholar
  23. 23.
    Farrar MA, Vucic S, Johnston HM, du Sart D, Kiernan MC. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr. 2013;162(1):155–9.PubMedGoogle Scholar
  24. 24.
    Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics. 2004;114(5):e548–53.PubMedGoogle Scholar
  25. 25.
    Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518–23.PubMedGoogle Scholar
  26. 26.
    Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–32.PubMedGoogle Scholar
  27. 27.
    Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin. 2014;32(3):671–688, viii.PubMedGoogle Scholar
  28. 28.
    Wein N, Alfano L, Flanigan KM. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Pediatr Clin N Am. 2015;62(3):723–42.Google Scholar
  29. 29.
    Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myologica : Myopathies Cardiomyopathies : Off J Mediterr Soc Myology. 2012;31(2):121–5.Google Scholar
  30. 30.
    Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve. 2007;36(4):424–35.PubMedGoogle Scholar
  31. 31.
    Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–72.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23(9):1344–7.PubMedGoogle Scholar
  33. 33.
    Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–45.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Creutzfeldt CJ, Robinson MT, Holloway RG. Neurologists as primary palliative care providers: communication and practice approaches. Neurol Clin Pract. 2016;6(1):40–8.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Levi BH, Simmons Z, Hanna C, et al. Advance care planning for patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degeneration. 2017;18(5–6):388–96.Google Scholar
  36. 36.
    Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci. 2011;304(1–2):44–8.PubMedGoogle Scholar
  37. 37.
    Katzberg HD, Benatar M, et al. Cochrane Database Syst Rev. 2011;1:Cd004030.Google Scholar
  38. 38.
    Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1:Cd011776.PubMedGoogle Scholar
  39. 39.
    Oliver D. The quality of care and symptom control–the effects on the terminal phase of ALS/MND. J Neurol Sci. 1996;139(Suppl):134–6.PubMedGoogle Scholar
  40. 40.
    Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–26.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140–7.PubMedGoogle Scholar
  42. 42.
    Arnulf I, Similowski T, Salachas F, et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2000;161(3 Pt 1):849–56.PubMedGoogle Scholar
  43. 43.
    Clemens KE, Klaschik E. Morphine in the management of dyspnoea in ALS. A pilot study. Eur J Neurol. 2008;15(5):445–50.PubMedGoogle Scholar
  44. 44.
    Rabkin J, Ogino M, Goetz R, et al. Tracheostomy with invasive ventilation for ALS patients: neurologists’ roles in the US and Japan. Amyotroph Lateral Scler Frontotemporal Degeneration. 2013;14(2):116–23.Google Scholar
  45. 45.
    Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227–33.PubMedPubMedCentralGoogle Scholar
  46. 46.
    McCullagh S, Moore M, Gawel M, Feinstein A. Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction. J Neurol Sci. 1999;169(1–2):43–8.PubMedGoogle Scholar
  47. 47.
    Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8):1364–70.PubMedGoogle Scholar
  48. 48.
    Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler : Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2011;12(2):109–12.Google Scholar
  49. 49.
    Roos E, Mariosa D, Ingre C, et al. Depression in amyotrophic lateral sclerosis. Neurology. 2016;86(24):2271–7.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Kurt A, Nijboer F, Matuz T, Kubler A. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs. 2007;21(4):279–91.PubMedGoogle Scholar
  51. 51.
    Chio A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017;16(2):144–57.PubMedGoogle Scholar
  52. 52.
    Brettschneider J, Kurent J, Ludolph A, Mitchell JD. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2008;3:Cd005226.Google Scholar
  53. 53.
    Hanisch F, Skudlarek A, Berndt J, Kornhuber ME. Characteristics of pain in amyotrophic lateral sclerosis. Brain Behav. 2015;5(3):e00296.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Chio A, Canosa A, Gallo S, et al. Pain in amyotrophic lateral sclerosis: a population-based controlled study. Eur J Neurol. 2012;19(4):551–5.PubMedGoogle Scholar
  55. 55.
    Stephens HE, Joyce NC, Oskarsson B. National study of muscle cramps in ALS in the USA. Amyotroph Lateral Scler Frontotemporal Degeneration. 2017;18(1–2):32–6.Google Scholar
  56. 56.
    Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;4:Cd004157.Google Scholar
  57. 57.
    Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology. 2016;86(16):1474–81.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: a review. Amyotroph Lateral Scler : Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2010;11(1–2):4–15.Google Scholar
  59. 59.
    Murphy J. Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Mot Neuron Disord : Off Publ World Fed Neurol, Res Group Mot Neuron Dis. 2004;5(2):121–6.Google Scholar
  60. 60.
    Blischak D, Lombardino L, Dyson A. Use of speech-generating devices: in support of natural speech. Augmentative Altern Commun (Baltimore, Md : 1985). 2003;19(1):29–35.Google Scholar
  61. 61.
    Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom management and end-of-life care in amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):889–908.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Gibbons CJ, Thornton EW, Young CA. The patient experience of fatigue in motor neurone disease. Front Psychol. 2013;4:788.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39(2):137–43.PubMedGoogle Scholar
  64. 64.
    Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61(9):1279–81.PubMedGoogle Scholar
  65. 65.
    Andersen PM, Gronberg H, Franzen L, Funegard U. External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci. 2001;191(1–2):111–4.PubMedGoogle Scholar
  66. 66.
    Bourry N, Guy N, Achard JL, Verrelle P, Clavelou P, Lapeyre M. Salivary glands radiotherapy to reduce sialorrhea in amyotrophic lateral sclerosis: dose and energy. Cancer Radiother : J Soc Fr Radiother Oncologique. 2013;17(3):191–5.Google Scholar
  67. 67.
    National Institute for Health and Care Excellence. Motor neurone disease: assessment and management https://www.nice.org.uk/guidance/NG42/chapter/Recommendations-planning-for-end-of-life. Accessed 1 Dec 2017.
  68. 68.
    Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurol. 2015;14(4):435–42.PubMedGoogle Scholar
  69. 69.
    Blanke C, LeBlanc M, Hershman D, Ellis L, Meyskens F. Characterizing 18 years of the death with dignity act in Oregon. JAMA Oncol. 2017;3(10):1403–6.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Tripodoro VA, De Vito EL. What does end stage in neuromuscular diseases mean? Key approach-based transitions. Curr Opin Support Palliat Care. 2015;9(4):361–8.PubMedGoogle Scholar
  71. 71.
    Chio A, Gauthier A, Calvo A, Ghiglione P, Mutani R. Caregiver burden and patients’ perception of being a burden in ALS. Neurology. 2005;64(10):1780–2.PubMedGoogle Scholar
  72. 72.
    Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75.PubMedGoogle Scholar
  73. 73.
    Lillo P, Mioshi E, Hodges JR. Caregiver burden in amyotrophic lateral sclerosis is more dependent on patients’ behavioral changes than physical disability: a comparative study. BMC Neurol. 2012;12:156.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Burke T, Elamin M, Galvin M, Hardiman O, Pender N. Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors. J Neurol. 2015;262(6):1526–32.PubMedGoogle Scholar
  75. 75.
    Mustfa N, Walsh E, Bryant V, et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology. 2006;66(8):1211–7.PubMedGoogle Scholar
  76. 76.
    National Hospice and Palliative Care Organization. Medicare hospice eligibility requirements. https://www.nhpco.org/hospice-eligibility-requirements, Dec 1, 2017.
  77. 77.
    McCluskey L, Houseman G. Medicare hospice referral criteria for patients with amyotrophic lateral sclerosis: a need for improvement. J Palliat Med. 2004;7(1):47–53.PubMedGoogle Scholar
  78. 78.
    Creutzfeldt CJ, Gooley T, Walker M. Are neurology residents prepared to deal with dying patients? Arch Neurol. 2009;66(11):1427–8.Google Scholar
  79. 79.
    Carver AC, Vickrey BG, Bernat JL, Keran C, Ringel SP, Foley KM. End-of-life care: a survey of US neurologists’ attitudes, behavior, and knowledge. Neurology. 1999;53(2):284–93.PubMedGoogle Scholar
  80. 80.
    Schuh LA, Biondo A, An A, et al. Neurology resident learning in an end-of-life/palliative care course. J Palliat Med. 2007;10(1):178–81.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyMayo ClinicJacksonvilleUSA
  2. 2.Department of Neurology, Neurological InstituteCleveland ClinicWest Palm BeachUSA

Personalised recommendations